LumiraDx SARS-CoV-2 Ag Testing

STONE Clinical Laboratories offers a rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform. Intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from nasal swab specimens collected from individuals suspected of COVID-19 by their healthcare provider within the first 12 days of symptom onset.

Antigen Testing Update

Stone Clinical Laboratories LLC, a CAP accredited and CLIA-certified laboratory in New Orleans, Louisiana, is excited to announce that beginning May 4th our lab has expanded its COVID-19 testing capacity to 5,000 tests per day since it first began accepting specimens for COVID-19 testing on March 19, 2020. In addition, Stone can now announce that it is able to perform up to 9,000 COVID-19 tests per day.

“Stone feels privileged to have the opportunity to rise to this challenge after introducing COVID-19 testing last month,” said Stone Clinical Laboratories’ founder and CEO, Christopher Ridgeway. “I am proud of the team we have here at Stone, first using their expertise and dedication to perform COVID-19 testing, and now continuing to apply that same diligence and expertise so that we can process even more tests for the community and introduce antibody testing. I can speak for all of us here at Stone that we are honored to play a part in the testing process for those effected by this national health crisis.” Learn More


Rapid Testing by microfluidic immunofluorescence assay – the better solution

    • 15 minutes TAT, allowing for quicker treatment
    • Reduced risk of specimen contamination
    • Easy-to-interpret test results
    • COVID-19 Testing is now available!

Lumira-Dx COVID Testing Fact Sheet for Healthcare Providers
Lumira-Dx COVID Testing Fact Sheet for Patients

Stone Clinical Laboratories